Pathological bases for a robust application of cancer molecular classification

International Journal of Molecular Sciences

Volumn 16, Issue 4, 2015, Pages 8655-8675

  Diaz Cano, Salvador J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Analytical genomic classification of tumors; Cancer; Cancer cell biology; Classification; Genomic pathology; Molecular pathology; Neoplasm

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER;

BIOINFORMATICS; CANCER CLASSIFICATION; CANCER GROWTH; CARCINOGENESIS; CELL LINEAGE; CHROMOSOMAL INSTABILITY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; INFLAMMATION; METASTASIS; MICROSATELLITE INSTABILITY; NEOPLASM; NEXT GENERATION SEQUENCING; PHENOTYPE; REVIEW; SCORING SYSTEM; TUMOR MICROENVIRONMENT; CLASSIFICATION; DNA SEQUENCE; GENETICS; METABOLISM; MOLECULAR DIAGNOSIS; NEOPLASMS;

BIOMARKERS, TUMOR; GENE EXPRESSION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR MICROENVIRONMENT;

EID: 84928141226     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16048655     Document Type: Review

References (110)

1. Blanes, A.; Sanchez-Carrillo, J.J.; Diaz-Cano, S.J. Topographic molecular profile of pheochromocytomas: Role of somatic down-regulation of mismatch repair. J. Clin. Endocrinol. Metab. 2006, 91, 1150–1158.
2. Arif, S.; Blanes, A.; Diaz-Cano, S.J. Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 2002, 41, 357–362.
3. Baithun, S.I.; Naase, M.; Blanes, A.; Diaz-Cano, S.J. Molecular and kinetic features of transitional cell carcinomas of the bladder: Biological and clinical implications. Virchows Arch. Int. J. Pathol. 2001, 438, 289–297.
4. Diaz-Cano, S.J. Designing a molecular analysis of clonality in tumours. J. Pathol. 2000, 191, 343–344.
5. Pozo-Garcia, L.; Diaz-Cano, S.J. Clonal origin and expansions in neoplasms: Biologic and technical aspects must be considered together. Am. J. Pathol. 2003, 162, 353–355.
6. Foulkes, W.D.; Clarke, B.A.; Hasselblatt, M.; Majewski, J.; Albrecht, S.; McCluggage, W.G. No small surprise–small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. J. Pathol. 2014, 233, 209–214.
7. Jelinic, P.; Mueller, J.J.; Olvera, N.; Dao, F.; Scott, S.N.; Shah, R.; Gao, J.; Schultz, N.; Gonen, M.; Soslow, R.A. et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat. Genet. 2014, 46, 424–426.
8. Witkowski, L.; Carrot-Zhang, J.; Albrecht, S.; Fahiminiya, S.; Hamel, N.; Tomiak, E.; Grynspan, D.; Saloustros, E.; Nadaf, J.; Rivera, B., et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat. Genet. 2014, 46, 438–443.
9. Diaz-Cano, S.J. General morphological and biological features of neoplasms: Integration of molecular findings. Histopathology 2008, 53, 1–19.
10. Diaz-Cano, S.J. Tumor heterogeneity: Mechanisms and bases for a reliable application of molecular marker design. Int. J. Mol. Sci. 2012, 13, 1951–2011.
11. Blay, J.-Y.; Bonvalot, S.; Casali, P.; Choi, H.; Debiec-Richter, M.; Dei Tos, A.P.; Emile, J.-F.; Gronchi, A.; Hogendoorn, P.C.W.; Joensuu, H., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20–21 march 2004, under the auspices of ESMO. Ann. Oncol. 2005, 16, 566–578.
12. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.; Stratton, M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4, 177–183.
13. Kho, A.T.; Zhao, Q.; Cai, Z.; Butte, A.J.; Kim, J.Y.H.; Pomeroy, S.L.; Rowitch, D.H.; Kohane, I.S. Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev. 2004, 18, 629–640.
14. Evans, A.S. Causation and disease: The henle-koch postulates revisited. Yale J. Biol. Med. 1976, 49, 175–195.
15. Berman, J.J. Tumor classification: Molecular analysis meets aristotle. BMC Cancer 2004, 4, 10.
16. Morgan, H.D.; Santos, F.; Green, K.; Dean, W.; Reik, W. Epigenetic reprogramming in mammals. Hum. Mol. Genet. 2005, 14, R47–R58.
17. Shiota, K.; Kogo, Y.; Ohgane, J.; Imamura, T.; Urano, A.; Nishino, K.; Tanaka, S.; Hattori, N. Epigenetic marks by DNA methylation specific to stem, germ and somatic cells in mice. Genes Cells 2002, 7, 961–969.
18. Allegrucci, C.; Thurston, A.; Lucas, E.; Young, L. Epigenetics and the germline. Reproduction 2005, 129, 137–149.
19. Esteller, M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br. J. Cancer 2007, 96, R26–R30.
20. Ooi, S.L.; Henikoff, S. Germline histone dynamics and epigenetics. Curr. Opin. Cell Biol. 2007, 19, 257–265.
21. Boorman, G.A.; Anderson, S.P.; Casey, W.M.; Brown, R.H.; Crosby, L.M.; Gottschalk, K.; Easton, M.; Ni, H.; Morgan, K.T. Toxicogenomics, drug discovery, and the pathologist. Toxicol. Pathol. 2002, 30, 15–27.
22. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70.
23. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
24. Kinzler, K.W.; Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87, 159–170.
25. Morrison, S.J.; Spradling, A.C. Stem cells and niches: Mechanisms that promote stem cell maintenance throughout life. Cell 2008, 132, 598–611.
26. Reddig, P.J.; Juliano, R.L. Clinging to life: Cell to matrix adhesion and cell survival. Cancer Metastasis Rev. 2005, 24, 425–439.
27. Tlsty, T.D.; Coussens, L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 2006, 1, 119–150.
28. Durrett, R.; Foo, J.; Leder, K.; Mayberry, J.; Michor, F. Intratumor heterogeneity in evolutionary models of tumor progression. Genetics 2011, 188, 461–477.
29. Diaz-Cano, S.J. Clonality studies in the analysis of adrenal medullary proliferations: Application principles and limitations. Endocr. Pathol. 1998, 9, 301–316.
30. Diaz-Cano, S.J.; Blanes, A.; Wolfe, H.J. Pcr techniques for clonality assays. Diagn. Mol. Pathol. 2001, 10, 24–33.
31. Laconi, E. The evolving concept of tumor microenvironments. BioEssays News Rev. Mol. Cell. Dev. Biol. 2007, 29, 738–744.
32. Laconi, E.; Doratiotto, S.; Vineis, P. The microenvironments of multistage carcinogenesis. Semin. Cancer Biol. 2008, 18, 322–329.
33. Laconi, E.; Sonnenschein, C. Cancer development at tissue level. Semin. Cancer Biol. 2008, 18, 303–304.
34. Huang, L.E.; Bindra, R.S.; Glazer, P.M.; Harris, A.L. Hypoxia-induced genetic instability—A calculated mechanism underlying tumor progression. J. Mol. Med. 2007, 85, 139–148.
35. Blagosklonny, M.V. Oncogenic resistance to growth-limiting conditions. Nat. Rev. 2002, 2, 221–225.
36. Breivik, J. The evolutionary origin of genetic instability in cancer development. Semin. Cancer Biol. 2005, 15, 51–60.
37. Bielas, J.H.; Loeb, L.A. Mutator phenotype in cancer: Timing and perspectives. Environ. Mol. Mutagen. 2005, 45, 206–213.
38. Blanes, A.; Diaz-Cano, S.J. Complementary analysis of microsatellite tumor profile and mismatch repair defects in colorectal carcinomas. World J. Gastroenterol. WJG 2006, 12, 5932–5940.
39. Rubio, J.; Blanes, A.; Sanchez-Carrillo, J.J.; Diaz-Cano, S.J. Microsatellite abnormalities and somatic down-regulation of mismatch repair characterize nodular-trabecular muscle-invasive urothelial carcinoma of the bladder. Histopathology 2007, 51, 458–467.
40. Bardelli, A.; Cahill, D.P.; Lederer, G.; Speicher, M.R.; Kinzler, K.W.; Vogelstein, B.; Lengauer, C. Carcinogen-specific induction of genetic instability. Proc. Natl. Acad. Sci. USA 2001, 98, 5770–5775.
41. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867.
42. Ellis, L.M.; Hicklin, D.J. Vegf-targeted therapy: Mechanisms of anti-tumour activity. Nat. Rev. 2008, 8, 579–591.
43. Yang, L.; Huang, J.; Ren, X.; Gorska, A.E.; Chytil, A.; Aakre, M.; Carbone, D.P.; Matrisian, L.M.; Richmond, A.; Lin, P.C., et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13, 23–35.
44. Blanes, A.; Diaz-Cano, S.J. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions. Hum. Pathol. 2006, 37, 1295–1303.
45. Blanes, A.; Rubio, J.; Martinez, A.; Wolfe, H.J.; Diaz-Cano, S.J. Kinetic profiles by topographic compartments in muscle-invasive transitional cell carcinomas of the bladder: Role of TP53 and NF1 genes. Am. J. Clin. Pathol. 2002, 118, 93–100.
46. Diaz-Cano, S.J.; Blanes, A.; Rubio, J.; Matilla, A.; Wolfe, H.J. Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder. Lab. Investig. J. Tech. Methods Pathol. 2000, 80, 279–289.
47. Jimenez, J.J.; Blanes, A.; Diaz-Cano, S.J. Microsatellite instability in colon cancer. N. Engl. J. Med. 2003, 349, 1774–1776.
48. Bissig, H.; Richter, J.; Desper, R.; Meier, V.; Schraml, P.; Schaffer, A.A.; Sauter, G.; Mihatsch, M.J.; Moch, H. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am. J. Pathol. 1999, 155, 267–274.
49. Cheng, L.; Bostwick, D.G.; Li, G.; Wang, Q.; Hu, N.; Vortmeyer, A.O.; Zhuang, Z. Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer 1999, 85, 2017–2022.
50. Kuukasjarvi, T.; Karhu, R.; Tanner, M.; Kahkonen, M.; Schaffer, A.; Nupponen, N.; Pennanen, S.; Kallioniemi, A.; Kallioniemi, O.P.; Isola, J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997, 57, 1597–1604.
51. Ramaswamy, S.; Ross, K.N.; Lander, E.S.; Golub, T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003, 33, 49–54.
52. Weigelt, B.; Glas, A.M.; Wessels, L.F.; Witteveen, A.T.; Peterse, J.L.; van’t Veer, L.J. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl. Acad. Sci. USA 2003, 100, 15901–15905.
53. Weigelt, B.; Hu, Z.; He, X.; Livasy, C.; Carey, L.A.; Ewend, M.G.; Glas, A.M.; Perou, C.M.; van’t Veer, L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005, 65, 9155–9158.
54. Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 2009, 15, 559–565.
55. Ruijter, E.T.; van de Kaa, C.A.; Schalken, J.A.; Debruyne, F.M.; Ruiter, D.J. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J. Pathol. 1996, 180, 295–299.
56. Alvarado, C.; Beitel, L.K.; Sircar, K.; Aprikian, A.; Trifiro, M.; Gottlieb, B. Somatic mosaicism and cancer: A micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res. 2005, 65, 8514–8518.
57. Shah, S.P.; Morin, R.D.; Khattra, J.; Prentice, L.; Pugh, T.; Burleigh, A.; Delaney, A.; Gelmon, K.; Guliany, R.; Senz, J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461, 809–813.
58. Holmgren, L.; O’Reilly, M.S.; Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995, 1, 149–153.
59. Bornstein, S.R.; Hornsby, P.J. What can we learn from gene expression profiling for adrenal tumor management? J. Clin. Endocrinol. Metab. 2005, 90, 1900–1902.
60. Garber, M.E.; Troyanskaya, O.G.; Schluens, K.; Petersen, S.; Thaesler, Z.; Pacyna-Gengelbach, M.; van de Rijn, M.; Rosen, G.D.; Perou, C.M.; Whyte, R.I., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 2001, 98, 13784–13789.
61. Steeg, P.S. New insights into the tumor metastatic process revealed by gene expression profiling. Am. J. Pathol. 2005, 166, 1291–1294.
62. Van de Rijn, M.; Rubin, B.P. Gene expression studies on soft tissue tumors. Am. J. Pathol. 2002, 161, 1531–1534.
63. Van’t Veer, L.J.; Paik, S.; Hayes, D.F. Gene expression profiling of breast cancer: A new tumor marker. J. Clin. Oncol. 2005, 23, 1631–1635.
64. Ouatas, T.; Salerno, M.; Palmieri, D.; Steeg, P.S. Basic and translational advances in cancer metastasis: Nm 23. J. Bioenerg. Biomembr. 2003, 35, 73–79.
65. Salerno, M.; Ouatas, T.; Palmieri, D.; Steeg, P.S. Inhibition of signal transduction by the nm23 metastasis suppressor: Possible mechanisms. Clin. Exp. Metastasis 2003, 20, 3–10.
66. Steeg, P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. 2003, 3, 55–63.
67. Steeg, P.S.; Ouatas, T.; Halverson, D.; Palmieri, D.; Salerno, M. Metastasis suppressor genes: Basic biology and potential clinical use. Clin. Breast Cancer 2003, 4, 51–62.
68. Wulfkuhle, J.D.; Paweletz, C.P.; Steeg, P.S.; Petricoin, E.F., III.; Liotta, L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv. Exp. Med. Biol. 2003, 532, 59–68.
69. Diaz-Cano, S.J. Paratumoral gene expression profiles: Promising markers of malignancy in melanocytic lesions. Br. J. Dermatol. 2011, 165, 702–703.
70. Peinado, H.; Lavotshkin, S.; Lyden, D. The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Semin. Cancer Biol. 2011, 21, 139–146.
71. Gyorgy, B.; Szabo, T.G.; Pasztoi, M.; Pal, Z.; Misjak, P.; Aradi, B.; Laszlo, V.; Pallinger, E.; Pap, E.; Kittel, A., et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cell Mol. Life Sci. 2011, 68, 2667–2688.
72. Guo, Y.; Feng, Y.; Trivedi, N.S.; Huang, S. Medusa structure of the gene regulatory network: Dominance of transcription factors in cancer subtype classification. Exp. Biol. Med. 2011, 236, 628–636.
73. Guo, Z.; Wu, F.; Asplund, A.; Hu, X.; Mazurenko, N.; Kisseljov, F.; Ponten, J.; Wilander, E. Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod. Pathol. 2001, 14, 54–61.
74. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358, 1148–1159.
75. Feinberg, A.P. The epigenetics of cancer etiology. Semin. Cancer Biol. 2004, 14, 427–432.
76. Diaz-Cano, S.J. Molecular mechanisms in melanoma. N. Engl. J. Med. 2006, 355, 1395–1396.
77. Fletcher, C.D.M.; Berman, J.J.; Corless, C.; Gorstein, F.; Lasota, J.; Longley, B.J.; Miettinen, M.; O’Leary, T.J.; Remotti, H.; Rubin, B.P., et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum. Pathol. 2002, 33, 459–465.
78. Medeiros, F.; Corless, C.L.; Duensing, A.; Hornick, J.L.; Oliveira, A.M.; Heinrich, M.C.; Fletcher, J.A.; Fletcher, C.D.M. Kit-negative gastrointestinal stromal tumors: Proof of concept and therapeutic implications. Am. J. Surg. Pathol. 2004, 28, 889–894.
79. Sakurai, S.; Hasegawa, T.; Sakuma, Y.; Takazawa, Y.; Motegi, A.; Nakajima, T.; Saito, K.; Fukayama, M.; Shimoda, T. Myxoid epithelioid gastrointestinal stromal tumor (gist) with mast cell infiltrations: A subtype of gist with mutations of platelet-derived growth factor receptor alpha gene. Hum. Pathol. 2004, 35, 1223–1230.
80. Laé, M.; Fréneaux, P.; Sastre-Garau, X.; Chouchane, O.; Sigal-Zafrani, B.; Vincent-Salomon, A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod. Pathol. 2009, 22, 291–298.
81. Makretsov, N.; He, M.; Hayes, M.; Chia, S.; Horsman, D.E.; Sorensen, P.H.B.; Huntsman, D.G. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 2004, 40, 152–157.
82. Leeman-Neill, R.J.; Kelly, L.M.; Liu, P.; Brenner, A.V.; Little, M.P.; Bogdanova, T.I.; Evdokimova, V.N.; Hatch, M.; Zurnadzy, L.Y.; Nikiforova, M.N.; et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer 2014, 120, 799–807.
83. Qi, M.; Li, Y.; Liu, J.; Yang, X.; Wang, L.; Zhou, Z.; Han, B. Morphologic features of carcinomas with recurrent gene fusions. Adv. Anat. Pathol. 2012, 19, 417–424.
84. Skálová, A.; Vanecek, T.; Majewska, H.; Laco, J.; Grossmann, P.; Simpson, R.H.W.; Hauer, L.; Andrle, P.; Hosticka, L.; Branžovský, J., et al. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: Report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am. J. Surg. Pathol. 2014, 38, 23–33.
85. Versteege, I.; Sévenet, N.; Lange, J.; Rousseau-Merck, M.F.; Ambros, P.; Handgretinger, R.; Aurias, A.; Delattre, O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998, 394, 203–206.
86. Chen, F.; Becker, A.J.; LoTurco, J.J. Contribution of tumor heterogeneity in a new animal model of cns tumors. Mol. Cancer Res. 2014, 12, 742–753.
87. Le Loarer, F.; Zhang, L.; Fletcher, C.D.; Ribeiro, A.; Singer, S.; Italiano, A.; Neuville, A.; Houlier, A.; Chibon, F.; Coindre, J.-M., et al. Consistent smarcb1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by fish in archival material. Genes Chromosomes Cancer 2014, 53, 475–486.
88. Vu-Han, T.-L.; Frühwald, M.C.; Hasselblatt, M.; Kerl, K.; Nagel, I.; Obser, T.; Oyen, F.; Siebert, R.; Schneppenheim, R. Identifying molecular markers for the sensitive detection of residual atypical teratoid rhabdoid tumor cells. Cancer Genet. 2014, 207, 390–397.
89. Vu-Phan, D.; Grachtchouk, V.; Yu, J.; Colby, L.A.; Wicha, M.S.; Koenig, R.J. The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype. Endocr. Relat. Cancer 2013, 20, 725–739.
90. Ricarte-Filho, J.C.; Li, S.; Garcia-Rendueles, M.E.R.; Montero-Conde, C.; Voza, F.; Knauf, J.A.; Heguy, A.; Viale, A.; Bogdanova, T.; Thomas, G.A., et al. Identification of kinase fusion oncogenes in post-chernobyl radiation-induced thyroid cancers. J. Clin. Investig. 2013, 123, 4935–4944.
91. Mackinnon, A.C.; Yan, B.C.; Joseph, L.J.; Al-Ahmadie, H.A. Molecular biology underlying the clinical heterogeneity of prostate cancer: An update. Arch. Pathol. Lab. Med. 2009, 133, 1033–1040.
92. Mehra, R.; Han, B.; Tomlins, S.A.; Wang, L.; Menon, A.; Wasco, M.J.; Shen, R.; Montie, J.E.; Chinnaiyan, A.M.; Shah, R.B. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases Cancer Res. 2007, 67, 7991–7995.
93. Fournier, G.; Valeri, A.; Mangin, P.; Cussenot, O. Prostate cancer. Epidemiology. Risk factors. Pathology. Ann. Urol. 2004, 38, 187–206.
94. Hodge, J.C.; Pearce, K.E.; Wang, X.; Wiktor, A.E.; Oliveira, A.M.; Greipp, P.T. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: Validation and clinical experience with 75 cases. Mod. Pathol. 2014, 27, 113–127.
95. Kobos, R.; Nagai, M.; Tsuda, M.; Merl, M.Y.; Saito, T.; Laé, M.; Mo, Q.; Olshen, A.; Lianoglou, S.; Leslie, C., et al. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein. J. Pathol. 2013, 229, 743–754.
96. Ross, H.; Argani, P. Xp11 translocation renal cell carcinoma. Pathology 2010, 42, 369–373.
97. Gulley, M.L.; Kaiser-Rogers, K.A. A rational approach to genetic testing for sarcoma. Diagn. Mol. Pathol. 2009, 18, 1–10.
98. Machado, I.; Traves, V.; Cruz, J.; Llombart, B.; Navarro, S.; Llombart-Bosch, A. Superficial small round-cell tumors with special reference to the ewing’s sarcoma family of tumors and the spectrum of differential diagnosis. Semin. Diagn. Pathol. 2013, 30, 85–94.
99. Riley, R.D.; Burchill, S.A.; Abrams, K.R.; Heney, D.; Sutton, A.J.; Jones, D.R.; Lambert, P.C.; Young, B.; Wailoo, A.J.; Lewis, I.J. A systematic review of molecular and biological markers in tumours of the ewing’s sarcoma family. Eur. J. Cancer 2003, 39, 19–30.
100. Mitelman, F.; Johansson, B.; Mertens, F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat. Genet. 2004, 36, 331–334.
101. Ramaswamy, S.; Tamayo, P.; Rifkin, R.; Mukherjee, S.; Yeang, C.H.; Angelo, M.; Ladd, C.; Reich, M.; Latulippe, E.; Mesirov, J.P., et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. USA 2001, 98, 15149–15154.
102. Tsai, Y.-S.; Lin, C.-T.; Tseng, G.C.; Chung, I.-F.; Pal, N.R. Discovery of dominant and dormant genes from expression data using a novel generalization of snr for multi-class problems. BMC Bioinform. 2008, 9, 425.
103. Golub, T.R.; Slonim, D.K.; Tamayo, P.; Huard, C.; Gaasenbeek, M.; Mesirov, J.P.; Coller, H.; Loh, M.L.; Downing, J.R.; Caligiuri, M.A., et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999, 286, 531–537.
104. Perez-Diez, A.; Morgun, A.; Shulzhenko, N. Microarrays for cancer diagnosis and classification. Adv. Exp. Med. Biol. 2007, 593, 74–85.
105. Statnikov, A.; Aliferis, C.F. Are random forests better than support vector machines for microarray-based cancer classification? AMIA Annu. Symp. Proc. 2007, 686–690.
106. Brownlee, N.A.; Perkins, L.A.; Stewart, W.; Jackle, B.; Pettenati, M.J.; Koty, P.P.; Iskandar, S.S.; Garvin, A.J. Recurring translocation (10;17) and deletion (14q) in clear cell sarcoma of the kidney. Arch. Pathol. Lab. Med. 2007, 131, 446–451.
107. Rakheja, D.; Weinberg, A.G.; Tomlinson, G.E.; Partridge, K.; Schneider, N.R. Translocation (10;17)(q22;p13): A recurring translocation in clear cell sarcoma of kidney. Cancer Genet. Cytogenet. 2004, 154, 175–179.
108. Meis-Kindblom, J.M. Clear cell sarcoma of tendons and aponeuroses: A historical perspective and tribute to the man behind the entity. Adv. Anat. Pathol. 2006, 13, 286–292.
109. Panagopoulos, I.; Mertens, F.; Isaksson, M.; Mandahl, N. Absence of mutations of the braf gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses). Cancer Genet. Cytogenet. 2005, 156, 74–76.
110. Covinsky, M.; Gong, S.; Rajaram, V.; Perry, A.; Pfeifer, J. EWS-ATF1 fusion transcripts in gastrointestinal tumors previously diagnosed as malignant melanoma. Hum. Pathol. 2005, 36, 74–81.